MX2019003726A - Metodos para tratar fibroides uterinos y endometriosis. - Google Patents

Metodos para tratar fibroides uterinos y endometriosis.

Info

Publication number
MX2019003726A
MX2019003726A MX2019003726A MX2019003726A MX2019003726A MX 2019003726 A MX2019003726 A MX 2019003726A MX 2019003726 A MX2019003726 A MX 2019003726A MX 2019003726 A MX2019003726 A MX 2019003726A MX 2019003726 A MX2019003726 A MX 2019003726A
Authority
MX
Mexico
Prior art keywords
subject
methods
endometriosis
reducing
uterine fibroids
Prior art date
Application number
MX2019003726A
Other languages
English (en)
Spanish (es)
Inventor
Hibberd Mark
Reddy Rajasekhar Vijaykumar
Mark Johnson Brendan
Seely Lynn
N Mudd Paul Jr
Wollowitz Susan
Tanimoto Masataka
Vasant Sukhatme Mayukh
Original Assignee
Myovant Sciences Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60915460&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2019003726(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Myovant Sciences Gmbh filed Critical Myovant Sciences Gmbh
Publication of MX2019003726A publication Critical patent/MX2019003726A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Surgical Instruments (AREA)
MX2019003726A 2016-09-30 2017-09-29 Metodos para tratar fibroides uterinos y endometriosis. MX2019003726A (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201662402150P 2016-09-30 2016-09-30
US201662402034P 2016-09-30 2016-09-30
US201662402055P 2016-09-30 2016-09-30
US201762492839P 2017-05-01 2017-05-01
US201762528409P 2017-07-03 2017-07-03
PCT/EP2017/074907 WO2018060501A2 (en) 2016-09-30 2017-09-29 Methods of treating uterine fibroids and endometriosis

Publications (1)

Publication Number Publication Date
MX2019003726A true MX2019003726A (es) 2019-09-26

Family

ID=60915460

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019003726A MX2019003726A (es) 2016-09-30 2017-09-29 Metodos para tratar fibroides uterinos y endometriosis.

Country Status (24)

Country Link
US (4) US11033551B2 (enExample)
EP (2) EP4094766B1 (enExample)
JP (1) JP7043503B2 (enExample)
CN (1) CN110312512B (enExample)
AU (2) AU2017336363B2 (enExample)
BR (1) BR112019006227A2 (enExample)
CA (1) CA3038879A1 (enExample)
CY (1) CY1125254T1 (enExample)
DK (1) DK3518933T4 (enExample)
ES (2) ES2912929T5 (enExample)
FI (1) FI3518933T4 (enExample)
HR (1) HRP20220708T4 (enExample)
HU (2) HUE059101T2 (enExample)
IL (2) IL300580B2 (enExample)
LT (1) LT3518933T (enExample)
MD (1) MD3518933T4 (enExample)
MX (1) MX2019003726A (enExample)
NZ (1) NZ752916A (enExample)
PL (2) PL3518933T5 (enExample)
PT (1) PT3518933T (enExample)
RS (1) RS63300B2 (enExample)
SI (1) SI3518933T2 (enExample)
SM (1) SMT202200254T1 (enExample)
WO (1) WO2018060501A2 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2912929T5 (en) 2016-09-30 2025-05-09 Sumitomo Pharma Switzerland Gmbh Methods of treating uterine fibroids and endometriosis
EP3518932B1 (en) 2016-09-30 2024-11-13 Sumitomo Pharma Switzerland GmbH Treatment of prostate cancer
EP4509173A3 (en) 2017-06-05 2025-06-04 Kissei Pharmaceutical Co., Ltd. Gonadotropin-releasing hormone antagonist dosing regimens for treating uterine fibroids and reducing menstrual blood loss
US11980621B2 (en) 2017-06-05 2024-05-14 Kissei Pharmaceutical Co., Ltd. Gonadotropin-releasing hormone antagonist dosing regimens for the treatment of endometriosis
JP2021531236A (ja) * 2018-04-19 2021-11-18 アッヴィ・インコーポレイテッド 重度の月経出血を治療する方法
MA54058A (fr) * 2018-10-29 2021-09-08 ObsEva SA Compositions et méthodes de traitement de l'endométriose interne et de l'endométriose rectovaginale
RU2711658C1 (ru) * 2019-04-16 2020-01-20 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт акушерства, гинекологии и репродуктологии имени Д.О. Отта" Способ лечения наружного генитального эндометриоза
CN110194776B (zh) * 2019-06-27 2021-05-28 四川伊诺达博医药科技有限公司 一种瑞卢戈利的合成方法
EP4009977A2 (en) * 2019-08-08 2022-06-15 ObsEva S.A. Compositions and methods for the treatment of estrogen-dependent disorders
CN115279769A (zh) 2019-10-10 2022-11-01 梦欧文科学有限责任公司 N-(4-(1-(2,6-二氟苄基)-5-((二甲基氨基)甲基)-3-(6-甲氧基-3-哒嗪基)-2,4-二氧代-1,2,3,4-四氢噻吩并[2,3-d]嘧啶-6-基)苯基)-n’-甲氧基脲的结晶形式
EP4041738A1 (en) * 2019-10-10 2022-08-17 Myovant Sciences GmbH Crystalline solvated forms of n-(4-(1-(2,6-difluorobenzyl)-5- ((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4- tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea
EP4107525A4 (en) * 2020-02-19 2024-08-14 Aspira Women's Health Inc. Compositions for endometriosis assessment having improved specificity
CN113384581B (zh) * 2020-03-12 2023-11-14 成都倍特药业股份有限公司 一种包含促性腺激素释放激素拮抗剂的药物组合物
CA3185151A1 (en) 2020-05-29 2021-12-02 Myovant Sciences Gmbh Combination solid oral dosage forms of gonadotropin-releasing hormone antagonists
EP4243829A1 (en) 2020-11-11 2023-09-20 Myovant Sciences GmbH Methods of administering relugolix
EP4419530A1 (en) 2021-10-18 2024-08-28 Sumitomo Pharma Switzerland GmbH Crystalline form of an ethanol solvate of n-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea
CN117069735A (zh) * 2022-05-10 2023-11-17 北京海美源医药科技有限公司 一种高效合成瑞卢戈利的方法和其应用
WO2024015934A2 (en) * 2022-07-13 2024-01-18 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods of diagnostic screening and early detection of adenomyosis
WO2024102620A2 (en) * 2022-11-09 2024-05-16 Tempest Therapeutics, Inc. Triazolone compounds and uses thereof
WO2025106820A1 (en) * 2023-11-16 2025-05-22 University Of South Florida Method of preventing progesterone contraceptive-induced abnormal uterine bleeding (aub)

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US402055A (en) 1889-04-23 Water-motor
US402034A (en) 1889-04-23 Dumping-wagon
US492839A (en) 1893-03-07 Key for brake-shoes
US402150A (en) 1889-04-30 Broadcast seed-sower
US528409A (en) 1894-10-30 Denis ahern
FR2512732A1 (fr) 1981-09-14 1983-03-18 Raffinage Cie Francaise Procede de fabrication d'objets composes d'un materiau rigide expanse a base de polychlorure de vinyle, objets obtenus par ce procede et leurs applications
US5340585A (en) 1991-04-12 1994-08-23 University Of Southern California Method and formulations for use in treating benign gynecological disorders
ECSP961635A (es) 1996-01-11 1997-06-27 Desprendimiento controlado de esteroides del recubrimiento de azucar
ECSP971998A (es) 1997-01-15 1998-04-07 Desprendimiento controlado de esteroides del recubrimiento de azucar
DE19815060A1 (de) 1998-04-03 1999-10-14 Jenapharm Gmbh Pharmazeutische Präparate zur Therapie von Nebenwirkungen während und/oder nach einer GnRHa-Therapie
US6265393B1 (en) * 1998-08-07 2001-07-24 Heinrichs William Leroy Prevention of endometriosis signs or symptons
TWI225863B (en) 1999-03-24 2005-01-01 Takeda Chemical Industries Ltd Thienopyrimidine compounds, their production and use
RU2233284C2 (ru) 1999-03-24 2004-07-27 Такеда Кемикал Индастриз, Лтд. Тиенопиримидиновые производные, способ их получения, фармацевтическая композиция и способ антагонизации гонадотропин-рилизинг гормона
WO2001064683A1 (en) 2000-02-29 2001-09-07 Takeda Chemical Industries, Ltd. Processes for the production of thienopyrimidine derivatives
WO2003064429A1 (en) 2002-01-30 2003-08-07 Takeda Chemical Industries, Ltd. Thienopyrimidines, process for preparing the same and use thereof
PT1591446E (pt) 2003-01-29 2013-06-12 Takeda Pharmaceutical Compostos de tienopirimidina e sua utilização
CA2531508C (en) 2003-07-07 2013-10-08 Neurocrine Biosciences, Inc. Pyrimidine-2, 4-dione derivatives as gonadotropin-releasing hormone receptor antagonists
MY151322A (en) 2004-04-30 2014-05-15 Bayer Ip Gmbh Management of breakthrough bleeding in extended hormonal contraceptive regimens
KR20080041662A (ko) 2005-07-22 2008-05-13 다케다 야쿠힌 고교 가부시키가이샤 조기 배란 예방제
TWI386417B (zh) 2005-12-22 2013-02-21 Takeda Pharmaceutical 轉移抑素衍生物及其用途
NZ580457A (en) 2007-04-06 2012-03-30 Neurocrine Biosciences Inc Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
US8765948B2 (en) 2007-11-07 2014-07-01 Neurocrine Biosciences, Inc. Processes for the preparation of uracil derivatives
WO2010026993A1 (ja) 2008-09-03 2010-03-11 武田薬品工業株式会社 製剤における吸収性改善方法および吸収性が改善された製剤
US9427418B2 (en) 2009-02-23 2016-08-30 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
US9624161B2 (en) 2009-02-23 2017-04-18 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
KR20160088947A (ko) 2010-06-16 2016-07-26 앙도르쉐르슈 인코포레이티드 에스트로겐-관련 질병의 치료 또는 예방 방법
JP2012077020A (ja) 2010-09-30 2012-04-19 Mochida Pharmaceut Co Ltd ゲスターゲンとＧｎＲＨアンタゴニストとの組合せ医薬
PT3415517T (pt) 2012-09-28 2022-05-13 Takeda Pharmaceuticals Co Forma cristalina de 1-(4-1-(2,6-difluorobenzil)-5- dimetilaminometil-3-(6-metoxipiridazin-3-il)-2,4-dioxo- 1,2,3,4-tetrahidrotieno(2,3-d)-pirimidin-6-il)fenil)-3- metoxiureia
WO2014143669A1 (en) 2013-03-15 2014-09-18 AbbVie Inc . Compositions for use in treating heavy menstrual bleeding and uterine fibroids
FI3263110T3 (fi) 2015-02-26 2023-07-25 Takeda Pharmaceuticals Co Tabletti, joka käsittää metoksiureajohdannaista ja mannitolipartikkeleita
US9949974B2 (en) 2015-09-01 2018-04-24 Abbvie Inc. Methods of adminstering elagolix
EP3518932B1 (en) 2016-09-30 2024-11-13 Sumitomo Pharma Switzerland GmbH Treatment of prostate cancer
ES2912929T5 (en) 2016-09-30 2025-05-09 Sumitomo Pharma Switzerland Gmbh Methods of treating uterine fibroids and endometriosis
US11980621B2 (en) 2017-06-05 2024-05-14 Kissei Pharmaceutical Co., Ltd. Gonadotropin-releasing hormone antagonist dosing regimens for the treatment of endometriosis
EP4041738A1 (en) 2019-10-10 2022-08-17 Myovant Sciences GmbH Crystalline solvated forms of n-(4-(1-(2,6-difluorobenzyl)-5- ((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4- tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea
CN115279769A (zh) 2019-10-10 2022-11-01 梦欧文科学有限责任公司 N-(4-(1-(2,6-二氟苄基)-5-((二甲基氨基)甲基)-3-(6-甲氧基-3-哒嗪基)-2,4-二氧代-1,2,3,4-四氢噻吩并[2,3-d]嘧啶-6-基)苯基)-n’-甲氧基脲的结晶形式
CA3185151A1 (en) 2020-05-29 2021-12-02 Myovant Sciences Gmbh Combination solid oral dosage forms of gonadotropin-releasing hormone antagonists
EP4243829A1 (en) 2020-11-11 2023-09-20 Myovant Sciences GmbH Methods of administering relugolix
EP4419530A1 (en) 2021-10-18 2024-08-28 Sumitomo Pharma Switzerland GmbH Crystalline form of an ethanol solvate of n-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea

Also Published As

Publication number Publication date
CA3038879A1 (en) 2018-04-05
WO2018060501A3 (en) 2018-05-11
EP3518933A2 (en) 2019-08-07
SI3518933T1 (sl) 2022-06-30
BR112019006227A2 (pt) 2019-06-18
US20240165118A1 (en) 2024-05-23
PT3518933T (pt) 2022-05-10
ES3018413T3 (es) 2025-05-16
US11793812B2 (en) 2023-10-24
EP4094766B1 (en) 2025-04-02
FI3518933T4 (fi) 2025-05-14
AU2022241582A1 (en) 2022-10-27
CN110312512A (zh) 2019-10-08
RS63300B1 (sr) 2022-07-29
CY1125254T1 (el) 2024-02-16
HUE072130T2 (hu) 2025-10-28
PL3518933T5 (pl) 2025-05-05
US20190262346A1 (en) 2019-08-29
SMT202200254T1 (it) 2022-07-21
ES2912929T3 (es) 2022-05-30
IL300580B1 (en) 2025-07-01
IL300580A (en) 2023-04-01
EP4094766A1 (en) 2022-11-30
US20220370462A1 (en) 2022-11-24
HUE059101T2 (hu) 2022-10-28
ES2912929T5 (en) 2025-05-09
MD3518933T2 (ro) 2022-07-31
AU2022241582C1 (en) 2024-11-28
IL265700B1 (en) 2023-03-01
JP7043503B2 (ja) 2022-03-29
CN110312512B (zh) 2023-05-09
US11033551B2 (en) 2021-06-15
LT3518933T (lt) 2022-06-10
AU2022241582B2 (en) 2024-06-13
MD3518933T4 (ro) 2025-10-31
NZ752916A (en) 2022-09-30
RS63300B2 (sr) 2025-05-30
DK3518933T3 (da) 2022-05-30
AU2017336363B2 (en) 2022-08-04
PL4094766T3 (pl) 2025-07-28
JP2019529575A (ja) 2019-10-17
WO2018060501A2 (en) 2018-04-05
SI3518933T2 (sl) 2025-05-30
PL3518933T3 (pl) 2022-06-20
US11957684B2 (en) 2024-04-16
US20210401841A1 (en) 2021-12-30
HRP20220708T4 (hr) 2025-04-25
IL265700B2 (en) 2023-07-01
IL300580B2 (en) 2025-11-01
DK3518933T4 (da) 2025-04-22
IL265700A (en) 2019-05-30
HRP20220708T1 (hr) 2022-07-22
EP3518933B1 (en) 2022-03-16
EP3518933B2 (en) 2025-02-26
AU2017336363A1 (en) 2019-05-16

Similar Documents

Publication Publication Date Title
NZ752916A (en) Methods of treating uterine fibroids and endometriosis
Chen et al. Discovery of N-(5-((5-chloro-4-((2-(isopropylsulfonyl) phenyl) amino) pyrimidin-2-yl) amino)-4-methoxy-2-(4-methyl-1, 4-diazepan-1-yl) phenyl) acrylamide (CHMFL-ALK/EGFR-050) as a potent ALK/EGFR dual kinase inhibitor capable of overcoming a variety of ALK/EGFR associated drug resistant mutants in NSCLC
MX2023001468A (es) Tratamiento de cancer de prostata.
NZ745957A (en) Heterocyclic amides useful as protein modulators
SG195141A1 (en) Combination of panobinostat and ruxolitinib in the treatment of cancer suchas a myeloproliferative neoplasm
EP4223298A3 (en) Compositions for use in treating heavy menstrual bleeding
MX369576B (es) Imidazoles 2-piridilo sustituidos como inhibidores de alk5 y/o alk4.
NZ708563A (en) Treatment of cancers using pi3 kinase isoform modulators
MX2019009501A (es) Compuestos de amino piridina utiles como inhibidores de ssao.
JP2013540823A5 (enExample)
PH12021551290A1 (en) Crf1 receptor antagonist, pharmaceutical formulations and solid forms thereof for the treatment of congenital adrenal hyperplasia
EA201791361A1 (ru) Терапия антагонистом рецепторов окситоцина в лютеиновую фазу для имплантации и беременности у женщин, проходящих процедуры вспомогательных репродуктивных технологий
BR112018075206A2 (pt) tratamento de malignidade hematológica com 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida
MX2015002005A (es) Combinacion de inhibidor de p13k e inhibidor de c-met.
PE20210096A1 (es) Inhibidor de ret para uso en tratar cancer que tiene una alteracion de ret
MX2022013530A (es) Combinación de terapia de células t dirigida a bcma y un compuesto inmunomodulador.
MX2024007444A (es) Inhibidores de cinasa met.
PH12017502100A1 (en) Selective progesterone receptor modulator (sprm) regimen
MX389041B (es) Regímenes de dosis de antagonista de oxitocina para promover la implantación embrionaria y prevenir abortos espontaneos.
EA201990857A1 (ru) Способы лечения миомы матки и эндометриоза
MY188267A (en) Progesterone receptor antagonist dosage form
ZA202402167B (en) Solid state forms of relugolix
MA46362B1 (fr) Méthodes de traitement des fibromes utérins et de l'endométriose
MX2014014813A (es) Uso de agonistas o antagonistas inversos para el receptor de grelina para tratar trastornos del sueño.
EA201990762A1 (ru) Способы лечения женского бесплодия